Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Rare Disease Treatment (2026-2031) - Expanding Orphan Drug Development Drives Market Growth

globenewswire.com
JNJ Johnson & Johnson (Janssen) is mentioned as a key player in the rare disease treatment market, indicating its involvement in this growing sector. The article does not provide specific sentiment towards JNJ but lists it among other major pharmaceutical companies. AMGN Amgen Inc. is listed as a company profile in the report, suggesting its participation in the rare disease treatment market. The article does not offer specific sentiment or details about Amgen's performance or outlook. PFE Pfizer Inc. is identified as a company with a profile in the rare disease treatment market. The article mentions it in the context of key players but does not provide specific sentiment or performance indicators. BMY Bristol Myers Squibb is listed as a company with a profile in the rare disease treatment market. The article includes it among key players without providing specific sentiment or detailed analysis. VRTX Vertex Pharmaceuticals is mentioned as a company with a profile in the rare disease treatment market. The article lists it among key players but does not offer specific sentiment or performance details. BMRN BioMarin Pharmaceutical is listed as a company with a profile in the rare disease treatment market. The article includes it among key players but does not provide specific sentiment or performance analysis. ULTA Ultragenyx Pharmaceutical is mentioned as a company with a profile in the rare disease treatment market. The article lists it among key players but does not offer specific sentiment or performance details. REGN Regeneron Pharmaceuticals is listed as a company with a profile in the rare disease treatment market. The article includes it among key players but does not provide specific sentiment or performance analysis. SRPT Sarepta Therapeutics is listed as a company with a profile in the rare disease treatment market. The article includes it among key players but does not provide specific sentiment or performance analysis. HRZN Horizon Therapeutics is mentioned as a company with a profile in the rare disease treatment market. The article lists it among key players but does not offer specific sentiment or performance details. PTC PTC Therapeutics is listed as a company with a profile in the rare disease treatment market. The article includes it among key players but does not provide specific sentiment or performance analysis.

Rare Disease Treatment (2026-2031) - Expanding Orphan Drug Development Drives Market Growth Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Rare Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Rare Disease Treatment Market Forecast to Reach USD 472.89 Billion by 2031, Growing at an 11.8% CAGR

The global rare disease treatment market is projected to expand from USD 242.5 billion in 2025 to USD 271.07 billion in 2026 before reaching USD 472.89 billion by 2031. The market is expected to register a compound annual growth rate of 11.8% from 2026 to 2031, supported by orphan-drug incentives, accelerated regulatory pathways, premium reimbursement frameworks, and rapid advances in gene and cell therapies.

Government Incentives Support Orphan-Drug Innovation

Extended market exclusivity, clinical trial tax credits, and regulatory incentives continue to reduce development risk across the rare disease treatment market. In the United States, orphan drugs can receive seven years of exclusivity, while eligible clinical research may qualify for a 25% tax credit. The European Union provides 10 years of market protection, which can extend to 12 years when pediatric requirements are fulfilled.

Priority Review Vouchers also strengthen the commercial potential of eligible treatments. These vouchers have been valued at approximately USD 150 million in recent transactions, including the sale associated with the approval of DAYBUE for Rett syndrome. Such programs encourage pharmaceutical and biotechnology companies to convert scientific discoveries into commercially viable therapies for small patient populations.

Expanding FDA and EMA Approval Pipelines Accelerate Market Growth

Regulatory agencies are increasingly using expedited review mechanisms to advance therapies for serious and underserved conditions. The U.S. Food and Drug Administration approved multiple gene therapies in 2024, including Kebilidi for aromatic L-amino acid decarboxylase deficiency. The European Medicines Agency granted 17 orphan designations in 2023, highlighting the continued flow of rare disease candidates into clinical development.

Programs such as the FDA's Support for Clinical Trials Advancing Rare Disease Therapeutics pilot and the EMA's Priority Medicines scheme are helping reduce regulatory uncertainty and shorten development timelines. These initiatives are expected to support faster product launches and sustained rare disease treatment market growth.

Small Patient Populations Remain a Clinical Trial Challenge

Recruiting sufficient participants for conventional randomized clinical trials remains difficult, particularly for ultra-rare diseases affecting only hundreds of people worldwide. Adaptive and basket trial designs offer greater flexibility, but recruitment gaps continue to affect research progress. More than half of rare disease studies fail to publish results, with limited enrollment representing a major contributing factor.

Other market influences include favorable reimbursement for high-value treatments, advances in precision medicine, and increasing investment in genetic therapies. However, payer resistance to six-figure and million-dollar treatment costs may limit patient access and place greater pressure on manufacturers to demonstrate durable clinical and economic value.

Rare Disease Treatment Market Segment Insights

Oncological rare diseases accounted for 41.89% of market revenue in 2025. This leadership reflects substantial unmet medical need and premium pricing for targeted cancer therapies, particularly biologics and immunotherapies used to treat hematologic malignancies. Continued approvals of precision medicines are expected to support steady growth across rare oncology indications.

Neurological disorders are forecast to expand at a 12.62% CAGR through 2031. Growth is being propelled by gene therapies such as Lenmeldy and Kebilidi, along with regulatory programs designed to accelerate treatments for severe neurological and neurodegenerative conditions. Approximately 18% of phase III rare disease assets now target neurological indications, signaling continued investment in this high-growth category.

Metabolic disorders remain an important market segment as enzyme replacement therapies and gene-editing technologies broaden long-term treatment options. Immunological disorders are benefiting from advances in monoclonal antibodies and engineered cell platforms, while infectious disease applications are attracting targeted investment in areas such as antimicrobial resistance.

Gene and Cell Therapies Lead Therapeutic Innovation

Biologics and monoclonal antibodies generated 50.74% of rare disease treatment market revenue in 2025, supported by established efficacy and payer familiarity with chronic treatment models. Gene and cell therapies, however, are projected to grow faster than all other therapy categories, recording a 12.88% CAGR through 2031.

More than 700 active clinical programs are evaluating gene and cell therapies for well-characterized and ultra-rare mutations. Recent approvals across neurological and hematologic diseases have validated adeno-associated virus platforms and encouraged investment in next-generation delivery technologies with improved tissue targeting.

Small-molecule drugs continue to play an important role in metabolic pathway modulation, offering oral convenience and lower manufacturing complexity. RNA-based therapies are also progressing, although adoption can be constrained by high annual costs. Vutrisiran, administered quarterly, may provide an administration and healthcare-utilization advantage over earlier treatments such as patisiran. Enzyme replacement therapies remain essential for lysosomal storage diseases, although single-administration gene therapies may gradually reshape treatment patterns.

Regional Rare Disease Treatment Market Outlook

North America held 41.86% of the global market in 2025, supported by FDA expedited pathways, broad commercial insurance coverage, and strong academic research networks. Orphan drugs typically launch two to three years earlier in the United States than in other regions. Canada also benefits from priority review procedures, although provincial budget limitations can delay consistent access.

Europe maintains a strong centralized regulatory framework, but varying national reimbursement policies create uneven access. Central and Eastern European markets currently reimburse fewer than half of approved rare disease therapies, highlighting significant opportunities for access reform.

Asia-Pacific is expected to record the fastest regional CAGR of 13.29% through 2031. China's expanded National Rare Diseases List and accelerated review initiatives are improving the development environment, while Japan remains a leader in ultra-rare neuromuscular treatments. South Korea and Singapore are also using tax incentives and clinical trial grants to attract multinational research.

Latin America, the Middle East, and Africa represent emerging opportunities as rare disease registries, diagnostic capacity, newborn screening programs, and procurement initiatives develop. Reimbursement uncertainty, currency volatility, and supply-chain constraints remain key barriers, but improving healthcare infrastructure is expected to support long-term market expansion.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Government incentives & global orphan-drug exclusivity

4.2.2 Growing FDA/EMA orphan-drug approvals pipeline

4.2.3 Premium pricing & favourable reimbursement frameworks

4.2.4 Rapid advances in gene & cell therapies

4.2.5 Distributed manufacturing for personalised gene therapy (under-the-radar)

4.2.6 AI-enabled virtual trials for ultra-rare cohorts (under-the-radar)

4.3 Market Restraints

4.3.1 Limited patient pools for conventional RCTs

4.3.2 Escalating payor push-back on six-figure price tags

4.3.3 Viral-vector manufacturing bottlenecks (under-the-radar)

4.3.4 Post-gene-therapy long-term safety liabilities (under-the-radar)

4.4 Value / Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Buyers

4.7.3 Bargaining Power of Suppliers

4.7.4 Threat of Substitutes

4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

5.1 By Disease Type

5.1.1 Oncological Rare Diseases

5.1.2 Neurological Disorders

5.1.3 Metabolic Disorders

5.1.4 Hematologic Disorders

5.1.5 Immunological Disorders

5.1.6 Infectious Diseases

5.1.7 Others

5.2 By Therapy Type

5.2.1 Small-Molecule Drugs

5.2.2 Biologics & Monoclonal Antibodies

5.2.3 Gene & Cell Therapy

5.2.4 RNA-based Therapy

5.2.5 Enzyme Replacement Therapy

5.2.6 Others

5.3 By Route of Administration

5.3.1 Oral

5.3.2 Parenteral

5.3.3 Others

5.4 By End User

5.4.1 Hospitals

5.4.2 Specialty Clinics

5.4.3 Home-Care Settings

5.4.4 Research & Academic Institutes

5.5 By Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 United Kingdom

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 India

5.5.3.3 Japan

5.5.3.4 South Korea

5.5.3.5 Australia

5.5.3.6 Rest of Asia-Pacific

5.5.4 South America

5.5.4.1 Brazil

5.5.4.2 Argentina

5.5.4.3 Rest of South America

5.5.5 Middle East and Africa

5.5.5.1 GCC

5.5.5.2 South Africa

5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)

6.3.1 Novartis AG

6.3.2 Johnson & Johnson (Janssen)

6.3.3 Roche Holding AG

6.3.4 AstraZeneca plc (Alexion)

6.3.5 Amgen Inc.

6.3.6 Pfizer Inc.

6.3.7 Takeda Pharmaceutical Co.

6.3.8 Sanofi S.A.

6.3.9 Bristol Myers Squibb

6.3.10 Vertex Pharmaceuticals

6.3.11 BioMarin Pharmaceutical

6.3.12 CSL Behring

6.3.13 Ultragenyx Pharmaceutical

6.3.14 Regeneron Pharmaceuticals

6.3.15 Bluebird bio

6.3.16 Sarepta Therapeutics

6.3.17 Horizon Therapeutics

6.3.18 Genzyme (Sanofi)

6.3.19 PTC Therapeutics

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/qfqdyx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.